pp-220 Solution for infusion

Indication: Relapsed/refractory CD19/CD22-positive B-cell non-Hodgkin lymphoma (R/R B-NHL) Clinical stage: Phase 2 — Phase I/II registrational trial (first patient enrolled November 2021); Phase 2 portion approved by NMPA 2025; FDA Orphan Drug Designation received Modality: Biological (autologous fully human CD19/CD22 dual-targeted CAR-T cell therapy — NBE) Mechanism / Target: Dual-targeted chimeric antigen receptor recognising both CD19 and CD22 on B-cell surface; fully human CAR construct generated from IASO's proprietary fully-human antibody discovery platform (minimises immunogenicity vs. murine-derived constructs); simultaneous dual-antigen targeting reduces CD19 antigen escape — primary resistance mechanism for single-targeted CAR-Ts Route / form: IV infusion (single autologous infusion) Differentiation: World's first fully human dual CD19/CD22 CAR-T cell therapy; addresses CD19 antigen escape that limits tisagenlecleucel/axicabtagene in B-NHL; Phase 2 NMPA-approved 2025; FDA Orphan Drug Designation;